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ABSTRACT
Melanoma is the most lethal of skin cancers, in part because of its proclivity for 
rapid and distant metastasis. It is also potentially the most neurotropic cancer in terms 
of probability of CNS metastasis from the primary lesion. Despite surgical resection 
and radiotherapy, prognosis remains guarded for patients with brain metastases. 
Over the past five years, a new domain of personalized therapy has emerged for 
advanced melanoma patients with the introduction of BRAF and other MAP kinase 
pathway inhibitors, immunotherapy, and combinatory therapeutic strategies. By 
targeting critical cellular signaling pathways and unleashing the adaptive immune 
response against tumor antigens, a subset of melanoma patients have demonstrated 
remarkable responses to these treatments. Over time, acquired resistance to these 
modalities inexorably develops, providing new challenges to overcome. We review 
the rapidly evolving terrain for intracranial melanoma treatment, address likely and 
potential mechanisms of resistance, as well as evaluate promising future therapeutic 
approaches currently under clinical investigation.
INTRODUCTION
Melanoma comprises 4% of all skin cancers but 
is responsible for 80% of skin cancer-related deaths [1], 
in part because of its proclivity for metastasis [2]. Once 
disseminated, median overall survival averages 6–11 
months [3, 4]; overall survival is reduced to 4–5 months 
for metastases to the brain [5–7]. Until the last five years, 
treatment options for melanomas that have metastasized to 
the brain have been limited. Despite surgical resection and 
irradiation, a majority of patients experience rapid disease 
progression [8]. Minimal benefit has been observed with 
cytotoxic chemotherapy [9].
Recently, developments in molecular and 
immunological targeting have produced new therapeutics 
which have changed the landscape of melanoma treatment 
and prognosis. This review examines recent developments 
in targeted systemic treatment of advanced melanoma—
including BRAF inhibitors, MEK pathway inhibitors, 
the blockade of the CTLA-4 and PD-1/PD-L1 immune 
checkpoints, and other novel anti-neoplastic agents—
and highlight lessons learned from countering acquired 
resistance.
Epidemiology of intracranial melanomas
Melanoma is currently the sixth most common 
cancer in the United States, with the highest rate of 
untreated fatality among cutaneous malignancies [1]. Its 
rate of diagnosis is increasing more quickly than any other 
cancer in the nation, partially because of escalated sun-
seeking behavior in previous decades, greater community 
                                                                   Review
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awareness, and higher screening rates [10, 11]. UV light 
is recognized as the predominant environmental risk 
factor and triggers distinct subgroups of melanoma with 
respect to chronic sun damage versus acute high-intensity 
exposure [12]. Melanoma is one of the most likely cancers 
to metastasize to the central nervous system (CNS) 
following lung and breast cancer [13, 14], accounting for 
up to 10% of patients with brain metastases [15]. Most 
cases of intracranial melanoma metastasize from a dermal 
origin, with primary intracranial melanomas a rare entity 
[16]. Given the paucity of systematic treatment studies in 
primary intracranial melanomas, we focus on the more 
prevalent metastatic melanoma to the brain.
Melanoma is classified by the American Joint 
Commission on Cancer TNM staging system, with stages 
I and II designating primary site melanoma, stage III 
denoting metastasis to one or more lymph nodes, and stage 
IV indicating presence of distant metastasis to other sites of 
the body [3]. Intracranial metastatic melanoma is classified 
as stage IV disease, and is usually associated with extensive 
lymph node involvement and visceral dissemination [17]. 
Half to three-quarters of patients with advanced melanoma 
exhibit brain metastases [18], with associated peritumoral 
edema, mass effect, and hemorrhage attributed as the direct 
cause of mortality in 94.5% of patients with intracranial 
tumors [7, 19]. Risk determinants for intracranial 
melanoma metastasis include origin from the head, neck, 
or mucosal regions and ulcerated or nodular lesions [7, 20]. 
Prognosis for those with brain metastases depends on a 
range of factors, including number of metastatic sites, CNS 
symptoms, electrocochleography (ECOG) scores, elevated 
serum S100 protein, elevated serum lactate dehydrogenase, 
advanced age, gender, and Karnofsky performance status 
[20–22]. Of interest, primary features may also influence 
prognosis, including location of primary melanoma, 
invasiveness, size, ulceration, and density of surrounding 
lymphatics and blood vessels [20].
Conventional therapies for intracranial 
melanoma 
The high rate of intracranial metastasis presents a 
considerable challenge for the management of malignant 
melanoma. Surgery and irradiation are commonly 
employed as first-line treatments, but exert only modest 
effects on overall survival even in the presence of local 
control. Conventional chemotherapy in the form of 
alkylating agents (dacarbazine, temozolomide) also 
exhibits limited efficacy.
Surgery and/or SRS for single or oligo metastatic 
disease 
Resection of solitary or oligo-metastases followed 
by whole brain radiation therapy is classically associated 
with significant reduction in local recurrence [23–25], 
although the presence of multiple lesions confers poorer 
prognosis [26]. Even in the setting of multiple metastases, 
however, a lesion causing significant mass effect and 
neurologic compromise or near eloquent regions of the 
brain may be candidate for resection.
Stereotactic radiosurgery (SRS), independently 
or as adjuvant therapy to the resection cavity following 
surgery, has shown some efficacy in controlling multiple 
intracranial tumors, with optimal treatment ranges between 
10 and 20 Gy [27]. Indications include tumors that are 
smaller than 3 cm, in deep locations, without significantly 
associated edema, midline shift, or hydrocephalus, and 
relatively good prognosis. Tumor control rates with SRS 
alone have been reported to range from 40% to 75% 
[28–30], with a median survival of 8–10 months following 
initial diagnosis. 
WBRT as an adjunct to surgery/SRS
Adjuvant whole brain radiation therapy (WBRT) 
may reduce local recurrence in patients with metastatic 
melanoma, but does not necessarily improve overall 
survival [31], although higher doses of WBRT increases 
median survival from 13 months to 17 months [32]. In 
addition, the use of fractionated WBRT after resection 
(as opposed to focal or stereotactic radiosurgery) has 
been challenged due to high melanoma radioresistance 
rates [33] and associated complications such as 
radiation leukoencephalopathy, edema, and cognitive 
decline [34]. SRS plus WBRT may result in equivalent 
or better survival compared with surgery and WBRT 
alone, although the survival advantage remains modest 
[23, 35].
Palliative WBRT
Of note, primary administration of WBRT (e.g., 
30 Gy administered in 10 fractions) may be provided to 
patients who are not resection candidates due to location 
or number of metastases as a palliative measure. Median 
survival in these cohorts has been reported to increase 
from 2.1 months to 3.6- 4.8 months [7, 36–38].
Conventional chemotherapy
Conventional chemotherapies have been utilized 
for patients with extensive disease burden with limited 
success. Dacarbazine was the first FDA-approved 
chemotherapy for melanoma, but conferred an overall 
response rate of only 10–20%, with less than 5% complete 
response [39–41] and mean survival of less than 8 
months [42, 43]. Lack of efficacy has been attributed to 
an inability to transverse the blood-brain barrier (BBB) 
and the activity of efflux pumps such as breast cancer 
resistance protein and P-glycoprotein [44]. Fotemustine, a 
nitrosurea capable of crossing the BBB [45], subsequently 
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demonstrated marginally improved median progression-
free survival (PFS) by 1–2 months relative to dacarbazine, 
with response rates of 5–6% [46, 47].
Temozolamide is a well-tolerated systemic therapy 
that does not significantly improve objective response rate 
and progression free survival as a single agent, but may 
be promising in combination therapy with other drugs 
[48]. Recent phase 1/2 preliminary data for decitabine—a 
DNA methyltransferase inhibitor attenuating CpG 
methylation in metastatic melanoma—in combination with 
temozolamide indicated an overall response rate of 18% 
and a median overall survival of 12.4 months [49].
Prophylactic chemoprevention has shown 
reasonable success in several studies for cancers other than 
melanoma [50]. In the case of melanoma, as metastases 
employ integrin signaling to grow along blood vessels, 
future approaches may opt to administer integrin inhibiting 
agents (e.g., cilengitide) during early disease progression 
to delay intracranial colonization [51]. In practice, 
however, cancer chemoprevention is seldom utilized in 
the clinical setting [52].
Limits of conventional therapies
To date, conventional treatment options have 
provided limited strategies to target metastatic melanoma. 
Surgical resection and irradiation are often not feasible 
in many melanoma cases due to the multiplicity of 
intracranial metastases and their relative radioresistance. 
With emerging understanding of tumor heterogeneity 
across space and time [53], melanoma brain metastases 
also likely represent diverse entities with varying 
sensitivities to treatment and ready acquisition of 
resistance. Recurrent disease and progressive metastases 
further thwart the effectiveness of systemic therapies. 
In this backdrop, the advent of targeted therapies for 
metastatic melanoma in the past 5 years has offered 
renewed promise.
Mechanisms of melanoma metastasis to the 
brain
The identification of actionable mechanisms of 
metastasis in any cancer type remains a “holy grail” of 
cancer research, as disease dissemination is the main 
driver of mortality. Although much remains to be learned 
in our understanding of how melanoma cells metastasize 
to the brain, a number of mechanisms are likely to 
contribute to this process. 
Cerebral chemotaxis
Melanoma metastasis is facilitated by the well-
perfused dermal capillary and lymphatic network at its site 
of origin [54]. A combination of autocrine and paracrine 
factors influence melanoma chemotaxis and survival in 
the brain [55–57]. Melanoma cells express low-affinity 
neurotrophin receptors p75NTR and TrKc, which are 
positively regulated by nerve growth factor (NGF) and 
neutrophin-3 (NT-3), leading to enhanced production of 
extracellular matrix (ECM) degradative enzymes such 
as heparanase and culminating in the breakdown of the 
blood-brain barrier (BBB). Chemokines and their receptors 
are also implicated in preferential homing of melanoma 
cells to target sites, including CXC chemokine receptor 
4 (CXCR-4) and C-C chemokine receptor 7 (CCR-7) 
[58]. Recently, expression of the protein PLEKHA5 
has been demonstrated to be higher in cerebrotropic 
metastases compared to systemic melanomas, suggesting 
an additional biomolecular target for future study [59].
Cytokine signaling
Paracrine cytokine signaling by activated 
astrocytes and microglia may further stimulate tumor 
development. Vascular endothelial growth factor A 
(VEGF-A) and IL-6, in particular, promote accelerated 
growth and infiltration of melanoma cell lines in vitro 
with accompanying co-optation of peritumoral vessels 
and increased vascular permeability [60]. VEGF 
expression in melanoma metastases can be upregulated 
by loss of suppressor of cytokine signaling-1 and 
ensuing activation of signal transducer and activator of 
transcription 3 (STAT3) [61]. Other upregulated genes 
in advanced intracranial melanoma include angiopoietin-
like protein 4, cyclooxygenase-2 (COX-2), and matrix-
metalloproteinase-1 (MMP-1) [55].
Immune evasion
After seeding the CNS, melanoma metastases are 
subject to the unique immunologic environment provided 
by the brain. Interestingly, murine and human tumor cells 
have been shown to lose normal expression of the tumor 
suppressor PTEN after metastasis to the brain, but not to 
other organs, which is then reinstated after leaving the CNS 
environment. The mechanism of plasticity is postulated 
to be produced by astrocyte-dependent, epigenetically 
regulated protein downregulation, where astrocyte-derived 
exosomes arbitrate an intercellular exchange of PTEN-
targeting microRNAs to metastatic tumor cells, while 
depletion of these microRNAS or blockade of astrocyte 
exosome secretion effectively “rescues” PTEN expression 
and suppresses brain metastasis [62].
In contrast to the historic view of the CNS as an 
immunologically privileged compartment, bounded by 
the blood-brain barrier, research increasingly reveals 
that CNS antigens are in fact accessible to peripheral 
lymphoid tissues and able to mount significant anti-
tumoral immunity [63–65]. Furthermore, the number 
of intratumoral lymphocytes positively correlates with 
increased patient survival; metastatic melanoma patients 
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with brisk lymphocyte activity demonstrated 1.5–3 
times longer overall survival compared to those without, 
although this was not a brain-specific finding [66, 67]. 
Recently, a functional lymphatic network abutting the 
dural sinuses was identified that provides an anatomic 
conduit for immune cell influx and efflux to the CNS 
[68, 69]. Taken together, these data suggest that immune 
potentiation may be a potent strategy for targeting CNS 
metastases.
Molecularly targeted therapies for melanoma 
In 2011, the treatment of metastatic melanomas 
was revolutionized by FDA approval of two new agents: 
vemurafenib (Zelboraf®; Genentech, San Francisco, 
California, USA) and ipilimumab (Yervoy™; Merck, 
Kenilworth, New Jersey, USA). Both address critical and 
independent pathways of advanced melanoma growth: 
the mitogen-activated protein (MAP) kinase signaling 
pathway for vemurafenib [70, 71] and the CTLA-4 
signaling pathway for ipillimumab [72, 73]. These new 
therapies heralded a paradigm shift by providing rational 
targeted therapies for a disease with a poor prior history of 
treatment (Table 1).
Role of BRAF mutations in melanoma 
malignancy
Mutations in BRAF are the most common 
targetable genetic variant in advanced melanoma [74]. 
BRAF mutations are found in 40–60% of melanomas, 
with a valine to glutamic acid substitution at residue 
600 (V600E) as the most common variant (75–80%), 
followed by substitution to lysine (V600K, 17–22%) and 
arginine (V600R, 3–4%) [75, 76]. Differences in BRAF 
genetic variants (V600E vs. other mutations) appear to be 
dependent on patient demographics and primary disease 
site, with non-V600E tumors occurring more frequently in 
men, older patients, and truncal lesions [77, 78]. Tumors 
with non-V600E mutations also have a shorter disease-
free interval from diagnosis of primary melanoma to first 
distant metastasis compared to their V600E counterparts 
[78]. Prognosis is less favorable for non-V600E mutations 
as efficacy of targeted therapy is more limited [78].
Raf exists in three mammalian isoforms: ARAF, 
BRAF, and CRAF (also known as Raf-1), of which the 
latter two are proto-oncogenic. Mutant BRAF triggers 
constitutive activation of the MAPK/ERK pathway and is 
typically mutually exclusive of activating RAS mutations 
in tumors [74, 79]. Other BRAF-mediated mechanisms 
in melanoma include UV activation of BRAF-driven 
tumorigenesis through single nucleotide mutations in 
TP53 [80] and copper-promoted MEK1 phosphorylation 
of ERK [81]. Co-occurrence with telomerase reverse 
transcriptase (TERT) promoter mutations (found in 38% 
of melanomas) was observed to be more commonly 
associated with high-risk clinicopathologic characteristics 
[82], suggesting potential interplay of TERT promoter and 
BRAF mutations in melanoma evolution.
BRAF inhibitors for invasive melanoma
Vemurafenib is an inhibitor of the BRAF serine 
threonine kinase mutant and blocks its constitutive 
activation of the MAPK mitogenic signaling pathway. 
A phase 2, multi-center study of vemurafenib in 132 
previously treated BRAFV600 mutant metastatic melanoma 
patients showed a response rate of 53%, a median duration 
of response of 6.7 months, and a median overall survival 
of 15.9 months [83]. Interim analysis during a phase 3 
randomization of 675 previously untreated BRAFV600E 
mutant metastatic melanoma patients to vemurafenib 
or dacarbazine revealed significant benefit for the 
vemurafenib cohort; 80% of patients showed a reduction 
in tumor size, with over half showing a reduction of > 30% 
[71, 84]. Median overall survival (OS) and PFS both 
increased by 4–5 months in the vemurafenib arm.
Most initial clinical trials excluded patients with 
metastases to the CNS, unless such metastases had been 
definitively treated with no signs of progression or need 
for glucocorticoid therapy for 3 months or more prior to 
initiation of treatment [71]. Nevertheless, isolated reports 
emerged suggesting positive effects of vemurafenib 
in controlling growth and reducing mass effect for 
intracranial melanoma metastases with the BRAFV600E 
mutation [85]. A subsequent pilot study found that twice 
daily administration of vemurafenib at 960 mg was 
associated with >30% intracranial tumor regression in 
37% of patients and intracranial partial response in 16% 
[86]. In previously untreated patients, overall intracranial 
response was 39% in tumors with the BRAFV600E mutation 
and 7% in tumors with the BRAFV600K mutation. In 
BRAFV600-mutant melanoma patients who had received 
previous treatment for unresectable brain metastases, 
overall intracranial response was 31% and 22% for V600E 
and V600K mutant tumors, respectively [86]. Median OS 
and PFS were 5.3 months and 3.9 months; 92% of patients 
were discontinued from the study within 4 months due 
to disease progression. As the brain is a common site of 
treatment failure (20%–25%) in patients without known 
brain metastases who are treated with vemurafenib, 
this suggests that vemurafenib monotherapy may be 
insufficient for intracranial metastatic melanoma [87]. A 
phase 2 study evaluating vemurafenib in a larger group 
of BRAF-mutant patients with active brain metastases is 
currently underway (NCT01378975).
In recognition of the potential of BRAF inhibition, 
dabrafenib (Tafinlar®; Novartis, Mission Viejo, 
California, USA) has also been FDA-approved. Drug 
efficacy was demonstrated in patients with active brain 
metastases, something that was not originally evaluated 
for vemurafenib [88]. In a phase 2 trial of BRAFV600E or 
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Table 1: FDA-approved molecular and immune targeted therapies for melanoma
Drug Name Mechanism
Target 
tumor 
population
FDA 
Approval 
Date
FDA 
Recommended 
Administration 
Protocol
Response 
Rate Side Effects
Resistance 
Onset
Treatment options 
after onset of 
resistance
Molecular 
Targets
        
Vemurafenib 
(Zelboraf®)
BRAF 
V600E/K 
inhibitor
BRAF 
V600E/K 
mutant
August 
2011
960 mg 2x daily 30–39%, in 
intracranial 
patients86, 88
Novel primary malignancies, 
tumor promotion in 
BRAF wild-type patients, 
hypersensitivity reactions, 
dermatologic reactions, QT 
prolongation, hepatotoxicity, 
photosensitivity, 
opthamologic reactions94–96
7 months, 
frequent107–111
Anti-BRAF/MEK 
co-therapy, dual 
Ras-Mek-Erk/PI3K-
PKB inhibition, 
ERKi, intermittent 
dosing, combination 
of BRAFi with 
immunotherapies 
(e.g., anti-CTLA, 
anti-PD1, anti-
PD-L1)109–117, 119, 123–126
Dabrafenib 
(Tafinlar®)
BRAF 
V600E/K 
inhibitor
BRAF 
V600E/K 
mutant
May 2013 150 mg 2x daily 31–52%, in 
intracranial 
patients88–89
Novel prima
ry malignancies, tumor 
promotion in BRAF wild-
type patients, hemorrhage, 
venous thromboembolism, 
cardiomyopathy, ocular 
toxicities, febrile 
reactions, skin toxicity, 
hyperglycemia, glucose-6-
phosphate dehydrogenase 
deficiency94–96
Trametinib 
(Mekinist™)
MEK 
inhibitor
BRAF 
V600E/K 
mutant
January 
2014
2 mg 1x daily 54%100 Novel primary malignancies, 
tumor promotion in 
BRAF wild-type patients, 
hemorrhage, venous 
thromboembolism, 
cardiomyopathy, ocular 
toxicities, interstitial lung 
disease, skin toxicity, febrile 
reactions, hyperglycemia115
Cobimetinib 
(Cotellic®)
MEK 
inhibitor
BRAF 
V600E/K 
mutant
November 
2015
60 mg 1x daily for 
the first 21 days 
of each 28-day 
cycle until disease 
progression or 
unacceptable 
toxicity, in 
combination with 
vemurafenib
68%102 Central serous retinopathy, 
gastrointestinal events, 
photosensitivity, elevated 
aminotransferase levels, and 
an increased creatine kinase 
level102
9.9 months, 
frequent102
Immunotherapy         
Ipilimumab 
(Yervoy®)
CTLA-4 
inhibitor
Unrestricted March 
2011
3 mg/kg 
administered 
intravenously 
every 3 weeks
15–30%, in 
intracranial 
patients145
Immune-mediated 
enterocolitis, immune-
mediated hepatitis, 
immune-mediated 
dermatitis, immune-
mediated neuropathies, 
immune-mediated 
endocrinopathies148, 136
> 1 year, 
rare61
Other 
immunotherapies, 
histone-deacetylase 
inhibition, 
indomethacin, ACT, 
combination SRS and 
immunotherapy185–187
Nivolumab 
(Opdivo®)
PD-1 
inhibitor
Unrestricted December 
2014
3 mg/kg 
administered 
intravenously 
every 2 weeks
28%155 Immune-mediated 
pneumonitis, immune-
mediated colitis, immune-
mediated hepatitis, immune-
mediated nephritis and renal 
dysfunction, immune-
mediated hypothyroidism 
and hyperthyroidism155
Pembrolizumab 
(Keytruda®)
PD-1 
inhibitor
Unrestricted September 
2014
2 mg/kg 
administered 
intravenously 
every 3 weeks
37–38%156 Immune-mediated 
pneumonitis, immune-
mediated colitis, immune-
mediated hepatitis, immune-
mediated hypophysitis, 
immune-mediated nephritis 
and renal dysfunction, 
immune-mediated 
hyperthyroidism and 
hypothyroidism156
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BRAFV600K mutant melanoma metastases to the brain, 39% 
of previously untreated BRAFV600E patients demonstrated 
a response while 31% of BRAFV600E patients with disease 
progression following prior surgery or radiation therapy 
also demonstrated a response. Median OS was 31–33 
weeks for patients with BRAFV600E metastases, as compared 
to 16–22 weeks for those with BRAFV600K mutant tumors; 
PFS was 16 weeks for BRAFV600E patients and 8–16 weeks 
for BRAFV600K patients, depending on prior treatment 
status [88]. A phase 3 randomized trial for dabrafenib in 
250 patients with V600E-mutant stage III or IV melanoma 
showed a 50% response rate and an improved PFS over 
dacarbazine (5.1 vs. 2.7 months) [89].
Blood barrier efficacy for BRAF inhibitors
Although the mechanism of blood-brain transport 
is unclear, the response and improved survival curves in 
patients treated with BRAF inhibitors suggest some level 
of inhibitor penetrance in patients with active cranial 
melanoma metastases [86, 90]. It serves to note that a 
range of factors may play a role in penetrance efficacy, 
including the number and size of brain metastases, the 
presence of co-morbidities, neurological complications, 
and tumor mutation status [73, 91].
In animal studies, BRAF inhibitors have been shown 
to be substrates for barrier efflux pumps, with increases up 
to 10-fold in brain distribution for P-glycoprotein and breast 
cancer resistance protein-1 knockouts [92]. Greater CNS 
penetration is observed for dabrafenib than for vemurafenib 
under similar dosing schedules [93]. Development of 
delivery mechanisms inhibiting the activity of efflux 
transporters may further increase the therapeutic efficacy 
of BRAF inhibition in intracranial disease.
Side effects of BRAF inhibition 
Long-term administration of BRAF inhibitors 
has been observed to associate with a range of skin 
changes, febrile reactions, arthralgia, headache, venous 
thromboembolism, cardiomyopathy, and hyperglycemia 
[94]. More concerning, secondary malignancies including 
squamous cell carcinomas, secondary melanomas, and 
recurrence of pre-existing malignancies have also been 
reported [95, 96]. These are predominantly attributed to 
MAPK pathway activation and increased Ras activity in 
BRAF wild-type cells exposed to BRAF inhibitors [97], 
adding a cautionary note to avoid BRAF inhibitor therapy 
in melanoma patients without mutant BRAF status. 
MEK inhibition
The presence of BRAF mutation is also associated 
with enhanced and selective sensitivity to MEK 
inhibition in melanoma cells [98]. Concomitant with 
the development of BRAF inhibitors, several MEK 
inhibitors—including trametinib, selumitinib, and 
binimetinib [99]—have emerged in recent years, adding 
to the existing pharmacologic armamentarium. 
Trametinib (MekinistTM; Novartis, Mission Viejo, 
California, USA), a MEK 1/2 inhibitor, has shown 
therapeutic promise as either a monotherapy for BRAF-
mutant melanoma or in combination with dabrafenib. 
A phase 3 trial comparing trametinib to dacarbazine or 
paclitaxel in metastatic BRAFV600-mutant melanoma 
patients demonstrated significant improvement in median 
PFS and a 6-month survival rate of 81% despite a 47% 
crossover rate from the chemotherapy group [100]. Of 
note, only 4% of the patients receiving trametinib harbored 
a known brain metastasis at study enrollment. Combination 
therapy with dabrafenib or cobimetinib results in markedly 
improved response, with median PFS in phase 3 studies 
ranging from 9.3–9.9 months for combination treatment 
versus 8.8 months for dabrafenib alone [101] and 6.2 
months for cobimetinib alone [102]. Although these studies 
did not include patients with brain lesions, a number of 
phase 2 studies (COMBI-MB, co-BRIM3, NCT01978236) 
are currently investigating the effect of BRAF/MEK 
inhibitory therapy on active brain metastasis.
Cobimetinib (Cotellic®; Genentech, San Francisco, 
California, USA), another MEK inhibitor, appears to have 
a favorable profile when combined with vemurafenib 
in patients with advanced BRAF-mutant melanoma. 
Progression-free survival during a multi-center phase 3 
study was reported to reach 9.9 months in the combination 
group (vemurafenib + cobimetinib) and only 6.2 months 
in the control group (vemurafenib alone) [102]. Response 
rate in the combination arm was 68% versus 45% 
(control), with respective complete response rates of 10% 
and 4%. Vemurafenib and cobimetinib administered in 
combination was associated with some increase in toxicity, 
with rash, diarrhea, photosensitivity, and hepatic-enzyme 
abnormalities as adverse events. Incidence of secondary 
cutaneous cancers decreased with combination treatment. 
Patients with brain metastases were allowed to enroll so 
long as the lesion had been inactive for > 3 weeks.
As with BRAF inhibition, the CNS penetrance 
of MEK inhibition is unclear, although animal models 
suggest restriction by barrier efflux pumps [103]. Given 
that clinical trials have not included a substantial number 
of patients with brain metastases, future directions may 
include the exclusive testing of a CNS disease cohort to 
better evaluate blood brain barrier efficacy.
Acquired resistance to BRAF and MEK 
inhibition
One major drawback to BRAF inhibition is a 
rapid onset of resistance, with average time to acquired 
resistance to kinase inhibition being less than 7 months 
[104]. A majority of currently recognized resistance 
mechanisms culminate in Ras-Raf-MEK-ERK pathway 
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reactivation (Figure 2), mutation of downstream MEK1 
(also known as MAP2K1) kinase [105], activating 
mutations of neuroblastoma viral RAS oncogene homolog 
(NRAS) [106] and KRAS [107], and dimerization of 
alternatively spliced BRAF [108]. BRAFV600E copy number 
amplification (observed in 8–20% of resistant melanoma 
samples) [107, 109] and elevated CRAF transcription 
[110] can also re-instigate ERK phosphorylation. 
Activating MEK mutations are found in less than 15% of 
cases, with only a subset capable of driving resistance to 
BRAF inhibitors [109].
ERK-independent pathways are also implicated, 
including the PI3K-protein kinase B (PKB)-mechanistic 
target of rapamycin (mTOR) pathway and the caspase-
dependent apoptotic cascade. These pathways converge 
at formation of eukaryotic translation initiation complex 
4F (eIF4F), which confers resistance to inhibition of 
BRAF [111]. Platelet-derived growth factor receptor β 
(PDGFRβ) initiation of survival pathways auxiliary to 
MAPK [106] and EGFR upregulation have also been 
observed after development of resistance [112]. In 
addition, BRAF inhibitors may be subject to extrusion 
via efflux pumps expressed by blood-brain-barrier 
epitheliocytes [92], allowing increased transporter 
expression to provide a supplementary route for 
intracranial BRAF inhibitor resistance.
Multiple mechanisms of resistance can develop 
simultaneously. In an analysis of 100 resistant melanoma 
samples from 44 patients, 70% of tumors demonstrated 
a MAPK alteration and 22% demonstrated a PI3K-PKB 
alteration, with 20% of patients harboring at least two 
distinct mechanisms of resistance [107]. Awareness of such 
intratumoral heterogeneity may help steer strategies for 
countering acquired resistance to inhibitor therapy [109].
Overcoming BRAF and MEK inhibitor 
resistance
One strategy for countering resistance is to 
concurrently target multiple oncogenic pathway members. 
A phase 2 study comparing combination therapy with 
dabrafenib and trametinib to dabrafenib monotherapy 
Figure 1: Canonical MAP kinase signaling mediates critical cellular processes implicated in proliferation, 
differentiation, survival, and angiogenesis. BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib, 
selumitinib, and binimetinib) target the MAP kinase pathway to check tumor growth.
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observed an unprecedented overall survival rate of 23.8 
months in the co-therapy group [113]. Phase 3 comparison 
of dabrafenib/trametinib versus dabrafenib alone 
corroborated a slightly improved PFS with combination 
treatment (9.3 vs. 8.8 months) [114]. Notably, combination 
therapy was associated with a lower rate of cutaneous 
squamous cell carcinoma and hyperkeratoses compared 
to monotherapy inhibition, although higher rates of 
severe grade pyrexia were observed [114]. Patients with 
CNS dissemination were not included in these studies; 
the effect of BRAF/MEK inhibitor therapy on brain 
metastases is presently being investigated in phase 2 trials 
(NCT02039947, NCT02230306).
In comparison, sequential administration of a single-
agent MEK inhibitor following acquired dabrafenib or 
vemurafenib resistance has proven largely unfruitful. 
A phase 2 study of trametinib in BRAF inhibitor-naïve 
patients versus those previously treated with dabrafenib 
or vemurafenib demonstrated response rates only in the 
drug-naïve arm (25% vs. 0%; patients with active brain 
metastases excluded) [115]. This likely results from 
multiple factors, including tumor heterogeneity among 
patients, cross-resistance between BRAF and MEK, 
and the activation of alternative signaling pathways 
[107, 109, 116]. Interestingly, a phase 1/2 study evaluating 
dabrafenib/trametinib co-therapy following dabrafenib 
resistance showed response rates of 13% (enrollment 
included patients with > 3 month history of stable brain 
involvement); an additional 44% experienced disease 
stabilization of ≥ 8 weeks [117]. Patients receiving 
dabrafenib monotherapy for greater than 6 months before 
progression and subsequent co-therapy had a greater PFS 
compared to those with early progression after less than 6 
months of monotherapy (3.9 vs. 1.8 months). This indicates 
a potential role for combination therapy after acquired 
resistance, although effect sizes appear to be modest.
Figure 2: Mechanisms and pathways of acquired resistance following BRAF inhibitor therapy.
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Inhibition of ERK, further down the MAPK cascade, 
may offer additional benefit. ERK inhibition in vitro is 
more effective than MEK inhibition in the background of 
Ras mutations, MEK mutations, and BRAF amplication 
[118, 119]. As ERK belongs to the same pathway as 
BRAF, however, inhibition may have limited efficacy 
following resistance and may actually promote relief of 
ERK-driven negative feedback on Ras signaling [120].
Emerging evidence indicates that resistance to 
BRAF inhibitors confers cross-resistance to MEK 
inhibitors, and that targeting a single pathway may 
not be enough for long-term disease control [116]. In 
addition, suppression of either Raf-MEK-ERK or PI3K-
PKB signaling leads to greater activation of the alternate 
pathway, suggesting that inhibition of both pathways is 
necessary for response durability [121]. Preliminary 
clinical trials assessing dual pathway inhibition are 
currently underway [122].
An empirical model has also proposed a role for 
“drug holidays” in countering acquired resistance. A 
proportion of cells expressing mutant or amplified BRAF 
become dependent on BRAF inhibition for a selective 
advantage, and cessation of drug administration leads 
to tumor regression; a staggered regimen has been 
shown to delay onset of resistance in both mice and 
human xenograft cell lines [123]. Subsequent studies 
investigating aberrantly spliced BRAF showed greater 
rates of proliferation in the presence of PLX4720 (a next-
generation BRAF inhibitor) and increased sensitivity to 
BRAF inhibition after a period of cessation [124]. Reversal 
of acquired EGFR expression has also been observed 
in resistant cell lines after interruption of therapy [112]. 
Preliminary anecdotal evidence suggests that sensitivity 
can be re-acquired following treatment intermission [125, 
126]. A phase 2 trial is underway to evaluate long-term 
efficacy of intermittent dosing (2 weeks on, 2 weeks off) 
of BRAF inhibitor LGX818 in patients with BRAF mutant 
metastatic melanoma (NCT01894672).
Additional strategies to overcome resistance 
include combination of MAPK pathway inhibitors with 
immunotherapies. This arrangement is currently being 
evaluated in a phase 1 study with BRAFV600 mutant 
advanced melanomas [127]. Other strategies combining 
targeted therapies and immunotherapies with anti-
programmed cell death protein 1 (PD-1) are also in 
development, as are studies of programmed death ligand 1 
(PD-L1) checkpoint inhibitors [128]. Therapies combining 
BRAF inhibitor PLX4720 and anti-CCL2 or agonistic 
anti-CD137 antibodies have also shown significant 
antitumor activity in murine transplant and tumorigenesis 
models [129, 130].
Immunotherapy for metastatic melanoma
Immunotherapy represents one of the most dramatic 
advances in cancer therapy over the last 5 years, and 
the treatment of melanoma has unquestionably been at 
the forefront of this revolution. An integrated immune 
response involving both innate and adaptive compartments 
is responsible for countering malignancy by activating 
T-cells into an effector state in a two stage process [64] 
(Figure 3). First, naïve T cells must recognize tumor-
specific antigens presented by the MHC molecules on 
antigen presenting cells in secondary lymphoid tissue. 
The securement of antigen and its presentation to T 
cells is the definitive step in the afferent pathway of 
the immune response. Second, a costimulatory signal 
completes the activation, which is negatively regulated by 
several inhibitory molecules expressed on T cells, antigen 
presenting cells (APC), and tumor cells [131]. These 
antagonist signals are known as immune checkpoints and 
include cytotoxic T-lymphocyte antigen-4 (CTLA-4), an 
inhibitory receptor on lymphocytes which acts in the early 
priming phase of the immune response. The subsequent 
efferent pathway of adaptive immunity involves activated 
T cells homing to the tumor environment, where the PD-1/
PD-L1 receptor-ligand pair acts to dampen peripheral 
immune activity (Figure 4). Melanomas are capable of 
inciting robust immune responses, making immunotherapy 
options particularly relevant. Despite instigating a heavy 
T-cell response, however, a proportion of the total CD8+ 
T cells in melanoma patients are functionally unresponsive 
to melanoma antigens [132]. Melanoma somehow appears 
to be capable of rendering T-cells anergic in vivo, either 
through CTLA-4, PD-1, mutational burden, or other 
molecular means. The targeting of immune checkpoints 
thus provides an empiric methodology for increasing the 
endogenous anti-tumor response.
Recent experience with immune checkpoint 
inhibitors has resulted in impressively durable responses 
in a subset of patients, in comparison to higher response 
rates achieved with MAPK pathway inhibition that 
are often less durable [133]. This may potentially be 
explained by the plasticity of the immune response, 
allowing for adaptation to an evolving tumor, as opposed 
to molecularly targeted drugs that can be foiled by newly 
acquired mutations [134, 135].
Of note, although many of the novel 
immunotherapeutic agents cannot cross the blood-brain 
barrier, CD8+ cytotoxic T cells appear to be able to travel 
to the brain and mount a significant anti-tumor immune 
response [136, 137]. Supporting this evidence, recent 
findings have suggested an extensive dural lymphatic 
system that is capable of carrying both CSF and immune 
cells into the murine brain; further support for this system 
in humans remains to be demonstrated [68].
CTLA-4 inhibition
In cases of malignancy, as first shown by James 
Allison [138], CTLA-4 operates mechanistically by 
outcompeting the T-cell costimulatory molecule, CD28, for 
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binding to the antigen-presenting cell expressed activation 
ligands, CD80/CD86 (Figure 4A), which impairs cytolytic 
T-cell lymphocyte activation and clonal expansion [139], 
inhibition of helper T-cell activity, and enhancement 
of the immunosuppressive activity of regulatory T-cell 
units [140]. Inhibition of CTLA-4 leads to significantly 
increased immune recognition of tumor cells [141]. In 
patients with advanced melanoma, CTLA-4 inhibition 
has been observed to produce durable response rates in 
approximately a quarter of treated patients [142, 143].
In 2011, the FDA approved ipilimumab (Yervoy™), 
a human immunoglobulin (IgG1) antibody that binds 
and sequesters CTLA-4 with high affinity for treatment 
of unresectable or metastatic melanoma (Figure 4B). 
Ipilimumab significantly improved median overall 
survival for metastatic melanoma (10.1 vs. 6.4 months 
for control) in phase 3 clinical trials; on 5-year follow-
up, 15–30% of ipilimumab treated patients were still 
alive, suggesting striking response durability [136]. 
Combination ipilimumab and fotemustine demonstrated 
50% disease control for patients with brain metastases in 
a phase 2 trial, with a 12.7 month median survival and a 
3-year survival rate of 27.8% [144]. In another study of 
patients with previously untreated metastatic melanoma, 
ipilimumab combined with dacarbazine extended survival 
beyond dacarbazine alone (median survival of 11.2 vs. 9.1 
months, respectively) [142]. At 3 years, 20.8% of patients 
receiving combination ipilimumab/dacarbazine remained 
alive, compared to 12.2% for the dacarbazine arm. The 
almost 10% difference between survival curves for over 
36 months corroborates the ability of ipilimumab to drive 
long-term response rates in a small proportion of patients. 
A phase 2 multi-institutional trial evaluating the 
efficacy of high-dose ipilimumab (10 mg/kg 4x weekly) 
Figure 3: Immunologic recognition and elimination of tumors. Tumor antigen is presented by an antigen presenting cell (APC) 
on the major histocompatibility complex (MHC), which serves as the ligand for the T-cell receptor (TCR). A second costimulatory signal 
(CD80/86) binding to CD28 on the lymphocyte is necessary for T-cell effector phase activation.
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in intracranial melanoma demonstrated disease control 
in 24% of patients after three months, with 11% partial 
response, a portion of which were durable [145]. Of 
particular significance, these data suggest that ipilimumab 
in patients with CNS disease provides a similar measure 
of disease control as in those without CNS metastases; 
active intracranial disease had previously been excluded 
for all clinical trials with ipilimumab monotherapy. These 
findings indicate that ipilimumab may mitigate the poor 
prognosis of CNS disease, highlighting the systematic 
efficacy of immunotherapy. 
Importantly, concomitant steroid use may also 
have an effect on patient response. Although steroids 
may be thought to improve certain symptoms, they also 
exert an immunosuppressive effect. In the referenced 
phase 2 ipilimumab trial [145], patients not requiring 
corticosteroids for clinical or radiological control 
displayed the most favorable outcomes (24% versus 10% 
response rate), suggesting that steroid use may negatively 
influence ipilimumab efficacy. Of note, however, the 
cohort requiring corticosteroids displayed more severe 
symptoms, which could partially account for the decrease 
in response rate.
Follow-up for 177 advanced melanoma patients 
enrolled in the earliest ipilimumab trials demonstrated 
median response duration of up to 7 years [143]. Notably, 
a proportion of initially reported partial responses 
progressed into complete responses after a prolonged 
Figure 4: (A) Immune targets and (B) current immunotherapies under investigation for metastatic melanoma. APC, antigen presenting 
cell; CTLA-4, cytotoxic T-lymphocyte associated protein 4; MHC, major histocompatibility complex; PD-1, programmed cell death 1; PD-
L1, programmed cell death ligand 1; TCR, T-cell receptor; T-reg, regulatory T-cell
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period of time, with average complete response attained 
at 30 months after treatment initiation. This extensive 
temporal interval before achieving complete tumor 
response likely reflects the time necessary for T-cells to 
uncouple from CTLA-4 mediated inhibition, undergo 
activation, and subsequently infiltrate and eradicate the 
tumor. In support, melanoma biopsy after ipilimumab 
treatment shows clear evidence of tumor infiltrating 
lymphocytes (TIL) [146, 147].
Side effects of ipilimumab therapy include 
immune-mediated diarrhea, rash, adrenal insufficiency, 
and hypophysitis [148]. In a phase 3 trial of 676 patients, 
14 deaths (2%) were drug-related, half of which were 
associated with immune-related adverse events [136]. 
The mechanistic role of CTLA-4 during early stages 
of T-cell activation—which leads to a more diffuse and 
nonspecific activation pattern compared to effector phase 
regulation—may explain the gamut of immune-triggered 
adverse events observed in clinical studies.
PD-1 checkpoint inhibition
In comparison to the role of CTLA-4 early in T-cell 
activation, PD-1 and its ligands (PD-L1 and PD-L2) 
regulate the effector phase of T-cell activation (Figure 4A). 
PD-1 couples to ligand outside the lymph node in the 
peripheral tissues (e.g., the tumor cell microenvironment), 
leading to downregulation of effector function resulting 
in an “exhausted” phenotype and lymphocyte apoptosis 
[149]. PD-1 and PD-L1 expression colocalizes with TIL 
and circulating interferon-gamma in metastatic melanoma, 
suggesting a role in countering the host immune response 
[150]. Inhibition of the PD-1/PD-L1 axis in vitro 
reinstates T-cell eradication of melanoma cells [151]. 
PD-L1 expression is observed in approximately 47% of 
intracranial melanoma metastases [152].
Two PD-1 inhibitors have been approved by the 
FDA for the first-line treatment of metastatic melanoma 
(in September 2014 and January 2015, respectively): 
nivolumab (Opdivo®; Bristol-Myers Squibb, New York 
City, New York, USA) and pembrolizumab (formerly MK-
3475 or lambrolizumab; Keytruda®; Merck, Kenilworth, 
New Jersey, USA). Nivolumab confers significant 
improvement to overall survival when compared with 
dacarbazine in previously untreated non-BRAF-mutant 
melanoma patients [153]. As with CTLA-4 inhibition, 
the duration of response to nivolumab appears to be 
relatively long-lived when compared to other therapeutic 
modalities. A phase 1 trial showed a mean overall response 
rate of 28% in patients with advanced, previously treated 
melanoma, with 62% experiencing a response durability of 
a year or longer [154]. During subsequent follow-up, the 
median OS was 16.8 months across all dosing regimens 
(0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg), 
with a peak of 20.3 months at the 3 mg/kg dose [155]. 
By targeting effector phase lymphocytes, PD-1 inhibition 
exhibits a more restricted pattern of immune upregulation 
compared with CTLA-4 suppression, which grants fewer 
immune-mediated side effects and a shorter time lag 
before complete tumor response than with ipilimumab, as 
TILs are already present in metastases.
Pembrolizumab also appears promising in metastatic 
melanoma, with measurable response rates observed in 
37–38% of patients, tumor size reduction in 77%, and 
a median response durability of > 11 months at time of 
report [156]. In a 2016 trial, significant interim responses 
to anti-PD1 therapy in 39 patients with brain metastases 
were observed, with additional studies on intracranial 
melanomas presently underway [157].
Interestingly—and contrasting with molecular 
therapy—previous treatment with ipilimumab does not 
significantly affect the likelihood of mounting a sizeable 
tumor response with anti-PD1 therapy [156]. Additionally, 
severity of adverse events experienced with ipilimumab 
are not predictive of adverse events during second-line 
PD1 inhibition [158].
Studies evaluating PD-1 blocking antibodies 
specifically in patients with intracranial melanoma 
metastases are underway (NCT02374242, NCT02320058). 
Other anti-PD-1 antibodies in development include CT011 
and PDR001 [159]. Expression of PD-1 ligand (PD-
L1) by tumor lines is being investigated as a predictive 
biomarker with distinct genetic and morphological 
characteristics (e.g., increased aggressiveness) [160], with 
preliminary data suggesting that tumors lacking PD-L1 
expression are less likely to respond to PD-1 inhibition 
compared to tumors expressing PD-L1 [161]. Several 
PD-L1 antibodies, including BMS-936559 and MPDL-
3280A, are also under clinical testing. Initial evidence 
demonstrates that PD-L1 suppression induces durable 
melanoma regression, with an objective response rate of 
17% at 6 months [162].
Combinatorial immunotherapy
CTLA-4 and PD-1 co-inhibition offers an additional 
domain of clinical investigation. In an early clinical trial 
of combination nivolumab and ipilimumab in advanced 
melanoma patients, 53% of treatment-naïve patients had 
an objective response with rapid and extensive (80%) 
regression of tumor, although a number of adverse 
side effects—including hepatic, gastrointestinal, and 
renal events—were reported [163]. A more recent 
phase 1 study confirmed a response rate of 61% for 
ipilimumab/nivolumab combination therapy versus 11% 
for ipilimumab monotherapy, with complete response 
reported in 22% and 0%, respectively [164]. Accelerated 
approval of the combination for BRAF-mutant melanoma 
was granted by the FDA in January 2016. A phase 2 study 
investigating combination ipilimumab and nivolumab 
in active intracranial metastases is currently underway 
(NCT02320058).
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Of note, the CTLA-4 and PD-1 immunological 
pathways are complementary and nonredundant, with 
CTLA-4 inhibition affecting early T-cell activation in 
lymph nodes and PD-1 suppression affecting effector 
T cells in peripheral tissue. Interestingly, in an animal 
model of melanoma, CTLA-4 inhibition resulted in a 
higher proportion of TIL expressing PD-1 while PD-1 
inhibition led to increased TIL expression of CTLA-4 
[165]. Treatment with CTLA-4 or PD-1 monotherapy 
may trigger upregulation of compensatory checkpoint 
mechanisms, highlighting the therapeutic potential of 
targeting multiple immunological pathways.
Other immunotherapeutic treatments
Checkpoint inhibition is a recent evolution of long-
standing experience with immunotherapy in melanoma 
patients. Interleukin-2 (IL-2) has been FDA-approved 
since 1998 for advanced melanoma therapy, based on data 
from phase 2 studies [166, 167]. High-dose administration 
is associated with overall response rates of 16%, with 
penetration to all sites of disease, including the CNS. 
Median response durability is greater than six months; in 
5% of patients with metastatic spread, clinical benefit may 
be observed for decades [168]. At high concentrations, 
however, IL-2 is significantly toxic, causing capillary 
leak syndrome and increased cerebral edema, thereby 
restricting its therapeutic profile to patients without 
cardiopulmonary morbidities and with good performance 
status.
Adoptive cell transfer (ACT), another 
immunotherapy strategy, involves collection of 
lymphocytes, either TILs or blood T cells, from the patient, 
followed by ex vivo activation and expansion (e.g., through 
the use of chimeric antigen receptors (CAR), which are 
used to graft disease-targeted monoclonal antibodies onto 
T cells), and subsequent infusion of processed cells back 
into the patient to induce an immune response [169]. In a 
recent report of ACT in metastatic melanoma patients, an 
overall response rate of 56% was observed in 93 patients 
[170]. No relapses were reported within a follow-up of 
31 months among the 11% who achieved a complete 
response.
In addition, inhibition of auxiliary coinhibitory 
molecules—such as lymphocyte activation gene 
3 (LAG-3), indoleamine-2,3-dioxygenase (IDO), 
arginine deaminase, prostaglandin E2, VEGF, T-cell 
immunoglobulin domain and mucin domain 3 (TIM-3), 
IL-6, IL-10, and other cytokines—are currently in clinical 
trials (Figure 5). Preliminary clinical results have also 
suggested the plausibility of novel immunotherapeutic 
combinations, including ipilimumab and high-dose IL-2 
[143]. Other potential complementary therapies include 
vaccines and regulatory T-cell suppression. For intracranial 
melanoma metastases, combination of immunotherapeutic 
treatment with adjuvant SRS synergistically improves 
BBB permeability, stimulates cytokine release, and 
increases antigen presentation on melanoma surface cells, 
with durability rates of > 4 years [171–173].
Resistance mechanisms of immune escape
Resistance via immune escape has been reported 
for various immunotherapeutic treatments, although 
less frequently than with BRAF inhibition. Potential 
mechanisms include selection of antigen-deficient tumor 
variants, induction of T-cell tolerance, antigen loss, and 
inflammation-induced reversible loss of melanocytic 
antigens [63, 174]. Melanoma-associated antigens include 
tumor-associated testis-specific antigens (e.g., MAGE, 
BAGE, and GAGE), melanocyte differentiation antigens 
(e.g., Melan-A/MART-1, tyrosinase), and aberrantly 
expressed or mutated molecules (e.g., CDK4, beta-
catenin) [175].
Figure 5: Immunotherapy options beyond checkpoint inhibition.
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In conditions of increased lymphocytic cytotoxicity 
against melanoma antigens, a portion of tumor cells switch 
from a differentiated to a dedifferentiated phenotype 
in response to T-cell driven inflammation [176, 177]. 
This process is mediated by tumor necrosis factor alpha 
(TNFα), which camouflages tumor cells against the 
immune system and is reversible upon discontinuation 
of therapy and resolution of inflammation. Upregulation 
of immunosuppressive mechanisms in melanoma may 
also inhibit T-cell activation, including IDO, PD-L1/B7-
H1, and FoxP3+ regulatory T cells [178]. These factors 
serve as negative feedback mechanisms following T-cell 
infiltration, suggesting suppressive regulatory immune 
checkpoints as viable future clinical targets. 
In vitro experiments have also demonstrated a role 
for apoptosis regulation as a means of modulating tumor 
resistance, through downregulation of death receptors 
(DRs) and the TNF-related apoptosis-inducing ligand 
(TRAIL) cytotoxic pathway [179]. Resistant melanoma 
cell lines demonstrate DR5 downregulation and an inverted 
proportion of pro- versus anti-apoptotic molecules, the 
effects of which can be countered by histone deacetylase 
(HDAC) inhibitors. This category of compounds prevents 
silencing of pro-apoptotic genes by blocking HDAC from 
deacetylating histone moieties. One such drug, vorinostat, 
has received FDA approval for the treatment of cutaneous 
T-cell lymphoma. Delivery of chromatin remodeling drugs 
to immune-resistant melanomas may be able to counter 
acquired resistance by shifting the intracellular climate 
towards a pro-apoptotic status through increased DR 
expression. Indomethacin, a non-steroidal anti-inflammatory 
drug, has also been shown to enhance TRAIL-mediated 
apoptosis through upregulation of DR5 and down-
modulation of survivin in human melanoma cell lines [180].
Additional modalities of acquired resistance include 
mechanisms that interfere with T-lymphocyte activity 
within the melanoma microenvironment [181]. Multiple 
checkpoint molecules have been observed to dampen the 
immune response, including LAG-3, TIM-3, and B- and 
T-lymphocyte attenuator (BTLA) [182]. Immunotherapy 
may also confer a fitness advantage to melanoma 
subpopulations with loss of MHC expression, which 
renders the tumor effectually invisible to the adaptive 
immune system [63, 183].
Unlike with BRAF and MEK inhibitors, treatment 
failure with one immunotherapy does not preclude 
response to others; patients resistant to ipilimumab can still 
have a response to anti-PD-1, and vice versa [156, 184]. 
Interestingly, retreatment is possible in tumor recurrences 
[185, 186], suggesting the activation and expansion of 
a new cohort of T-cells specific to the evolving tumor 
antigen repertoire.
Current knowledge regarding clinical benefits of 
immunotherapy may provide guidance for future trials 
of novel agents with respect to metastatic melanoma. 
Drugs with low response rates sustained by intratumoral 
lymphocyte infiltration—e.g., anti-CTLA4 antibodies—
should focus on response durability as the main trial 
endpoint [187]; agents with high response rates and well-
characterized mechanisms should focus on clinically 
meaningful duration. Combination immunotherapies, in 
turn, should focus on increased durability of response rates 
after addition of the co-therapeutic agent. Pharmacokinetic 
aspects relative to tumor penetrance, drug concentration in 
tumor cells, molecular stability, and receptor occupancy 
should also be noted. Improved characterization of drugs 
under development may accelerate and streamline trial 
design and meaningful interpretation of clinical endpoints.
CONCLUSIONS
Since 2011, seven novel agents have been introduced 
for targeted treatment of late-stage melanoma, including 
patients with intracranial disease—vemurafenib, dabrafenib, 
trametinib, cobimetinib, ipilimumab, nivolumab, and 
pembrolizumab. Therapeutic choices should be personalized 
based on multiple factors: BRAF mutational status, 
comorbidities, tumor burden, and immune status. 
Current consensus in the literature indicates that 
patients with BRAF mutant brain tumors should receive 
a BRAF inhibitor or combinatorial therapy with BRAF 
and MEK co-inhibition. There is no definitive clinical 
evidence suggesting that one inhibitor outperforms the 
other, although consideration should be taken regarding 
side effects. The rising epidemic of BRAF inhibitor 
resistance, as a consequence, invokes increasing 
combinatorial strategies for treatment of BRAF-mutant 
metastatic melanoma. Immunotherapy offers additional 
treatment options in exploiting the endogenous immune 
system to destroy metastatic tumor, with strikingly 
durable responses of several years in some. In addition, 
conventional treatments such as surgery and radiation 
continue to play a role in control of tumor progression for 
select clinical indications.
Despite the new ammunition against metastatic 
melanoma over the past five years, prognosis remains 
guarded. Further investigations into countering resistance, 
minimizing toxicity, optimizing combination therapies, 
and improving survival remain critically needed. By 
formulating a better framework for understanding the 
efficacy and limitations of current therapeutic modalities, 
improved prognoses and disease management may be 
attainable for intracranial melanoma diagnoses.
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